Description
CJC-1295 with DAC is a synthetic 30-amino-acid growth hormone-releasing hormone (GHRH) analog incorporating a Drug Affinity Complex (DAC) modification — a maleimidopropionic acid (MPA) linker conjugated to the C-terminal lysine residue. This DAC chemistry allows the peptide to form a covalent bond with circulating plasma albumin, extending the peptide’s effective half-life from minutes (native GHRH or CJC-1295 No DAC) to approximately 6-8 days in research models. The base sequence is identical to CJC-1295 No DAC (Modified GRF 1-29) with four amino acid substitutions versus native GHRH: D-Ala at position 2 (DPP-IV resistance), Gln at position 8, Ala at position 15, and Leu at position 27. CJC-1295 with DAC has been investigated in academic and clinical research literature for sustained GHRH receptor (GHRHR) pharmacology, albumin-conjugate peptide chemistry, prolonged-action GHRH analog SAR studies, and comparative pharmacology versus shorter-acting GHRH analogs (Sermorelin, Tesamorelin, and CJC-1295 No DAC). This compound is offered for laboratory research applications studying albumin-binding peptide chemistry and sustained-action GHRH receptor pharmacology.
Benefits (Research Focus)
• GHRH receptor pharmacology — studied for GHRHR binding activity and downstream cAMP/PKA signaling cascade research
• DAC albumin-binding chemistry — investigated for the maleimidopropionic acid (MPA) DAC linker and covalent albumin conjugation chemistry
• Half-life extension research — explored for prolonged plasma half-life (~6-8 days) via covalent albumin binding versus minutes for non-DAC analogs
• Comparative GHRH analog SAR — examined alongside Sermorelin, Tesamorelin, and CJC-1295 No DAC for GHRH analog structure-activity relationships
• Sustained-action peptide research — researched as a model compound for long-acting peptide therapeutic chemistry
What Researchers Look At
• GHRH receptor (GHRHR) binding affinity and cAMP/PKA signaling cascade activation in cell research models
• Albumin conjugation kinetics and stability of the MPA-albumin covalent bond
• Comparative pharmacokinetic profiles versus Sermorelin (~10 min t½), CJC-1295 No DAC (~30 min t½), and Tesamorelin
• DPP-IV resistance and peptidase stability research (D-Ala²-mediated)
• Comparative pharmacology across the broader GHRH analog research compound class
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 5 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: CJC-1295 with DAC
• Synonyms: CJC-1295 DAC; Modified GRF(1-29) with DAC; DAC:GRF; CJC-1295 with Drug Affinity Complex; long-acting GHRH analog
• Class: Synthetic 30-amino-acid GHRH analog; albumin-binding DAC conjugate; prolonged-action GHRH receptor research compound
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys (30 amino acids, with MPA-DAC modification at the C-terminal lysine)
• Key modifications: D-Ala² (DPP-IV resistance), Gln⁸, Ala¹⁵, Leu²⁷ (substitutions vs native GHRH), plus C-terminal Lys³⁰ with MPA linker for albumin conjugation
• Formula: C165H269N47O46
• Molecular Weight: ~3647.9 g/mol
• CAS: 863288-34-0
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• [COA links for the CJC-1295 with DAC 5mg batch to be added once Janoshik testing is complete]
